Shares of ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.55 and traded as low as $0.0851. ProPhase Labs shares last traded at $0.0857, with a volume of 4,907 shares trading hands.
ProPhase Labs Stock Performance
The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The stock’s 50-day moving average is $0.11 and its 200 day moving average is $0.55. The firm has a market cap of $516,085.40, a P/E ratio of -0.02 and a beta of 0.15.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in shares of ProPhase Labs during the second quarter worth about $40,000. Accretive Wealth Partners LLC acquired a new position in shares of ProPhase Labs in the 3rd quarter valued at approximately $114,000. Finally, Susquehanna International Group LLP grew its position in shares of ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares during the period. 9.45% of the stock is owned by institutional investors and hedge funds.
About ProPhase Labs
ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.
In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.
Featured Articles
- Five stocks we like better than ProPhase Labs
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
